following settlements reached us authorities pharmaceutical companies resolve allegations offlabel promotion drugs federal food drug cosmetic act illegal pharmaceutical companies promote products uses approved food drug administration fda corporations market drugs offlabel indications may subject civil liability false claims act well criminal penalties descriptions lawsuits listed chronological order whistleblower david franklin left position medical liaison parkedavis pharmaceutical division warnerlambert company learning companys marketing strategy promote epilepsy drug neurontin uses approved franklin attorney thomas greene filed lawsuit franklin v parkedavis false claims act federal district court boston first offlabel promotion case ever litigated whistleblower suit false claims act settlement announced eight years litigation may warnerlambert agreed pay million resolve civil criminal liability million going franklin participation one largest recoveries pharmaceutical company us history total settlement remained largest pharmaceutical company nonintervened false claims act case july settlement celgene corporation exceeded civil settlement case million civil component parkedavis case settled reference serono swiss biotechnology company obtained approval fda drug serostim treat aids wasting condition aids patients experience rapid weight however around time advent robust protease inhibitors could interact aids cocktails markedly slow advancement syndrome led decline symptoms aids wasting consequently demand result according prosecutors serono devised marketing scheme definition aids wasting would changed measure loss body cell mass company created computerized medical test designed detect loss body cell mass thereby diagnose aids wasting even patients experienced weight serono ultimately agreed pay million resolve civil criminal liability five whistleblowers former employees serono initiated complaints false claims act ultimately leading governments investigation whistleblowers shared million reward scheringplough pleaded guilty one count conspiracy make false statements medicaid program connection pricing allergy drug claritin allegations offlabel promotion however centered offlabel promotion several cancer drug temodar approved food drug administration fda treatment specific type brain tumor allegedly promoted treatment types brain cancer approved scheringplough allegedly promoted intron meanwhile use superficial bladder cancer hepatitis c case arose claims filed false claims act company forced pay million criminal fine additional million settle civil intermune abandoned efforts develop drug actimmune goes generic name interferongamma treatment idiopathic pulmonary fibrosis ipf chronic lung condition experimental trials showed drug ineffective treating decision announced company agreed pay million resolve criminal charges civil liability connection intermunes offlabel promotion drug approved fda treat chronic granulomatous disease severe malignant osteopetrosis extremely rare illnesses would generated sales million year sales drug treat ipf however soared high million year intermunes yearly sales entirely qui tam suit filed false claims act whistleblower james marchese cell therapeutics agreed settle claims million illegally promoted cancer drug trisenox approval fda treat relatively rare form leukemia known acute promyelocytic leukemia manufacturer promoted trisenox effective treatment cancers drug settlement million resolved allegations medicis pharmaceutical promoted loprox topical skin preparation use children age despite fact use children approved fda according government whistleblower complaint filed four former medicis sales representatives false claims act pediatricians urged prescribe loprox treatment diaper four relators shared reward providing information orphan medical subsidiary jazz pharmaceuticals pleaded guilty felony misbranding fdca agreed pay million resolve civil claims criminal charges connection xyrem drug approved fda narcolepsy street version classified drug enforcement administration schedule although drugs distribution narcolepsy medication strictly regulated complaint filed false claims act alleged company promoted drug treatment depression insomnia fibromyalgia case later overturned drug found effective insomnia fibromyalgia second circuit court appeals expanded first amendment commercial speech protection realm pharmaceutical marketing united states v caronia court overturned pharmaceutical sales representative conviction arising recording promotion offlabel use xyrem sodium oxybate group doctors xyrem approved indication excessive daytime sleepiness caronia promoted insomnia fibromyalgia court held convicting sales representative offlabel marketing untruthful misleading violated first amendment rights contrast offlabel promotion untruthful misleading would fraudulent thus protected first settlement totaling million settle host civil charges civil liabilities related alleged illegal pricing marketing practices several drugs bristolmyers squibb paid approximately million settle seven qui tam suits filed false claims specifically company engaged offlabel promotion abilify antipsychotic drug approved fda treat adult schizophrenia bipolar disorder government alleged bristol promoted drug pediatric use treat dementia offlabel cephalon pennsylvaniabased drug company paid million million paid resolve criminal indictment violations fdca million dispose claims brought false claims act four qui tam relators filed suits collectively recovered fda approved actiq fentanyl product manufactured lollipop use cancer patients morphinebased painkillers longer effective according government cephalon promoted actiq use noncancer patients treat conditions migraines sicklecell pain crises gabitril meanwhile received fda approval treatment partial seizures manufacturer allegedly marketed drug anxiety insomnia provigil initially approved treat excessive daytime sleepiness resulting narcolepsy later approved drug label indications cephalon allegedly promoted provigil fiveyear period nonstimulant drug treatment sleepiness tiredness decreased activity lack energy four whistleblowers initially filed suits false claims act prompting government investigation eli lilly company agreed plead guilty pay billion promoting drug zyprexa uses approved specifically private whistleblower complaints government alleged eli lilly engaged marketing scheme period several years promote drugs use children elderly groups particularly vulnerable products side antipsychotic drug initially approved treat manifestations certain psychotic disorders governments indictment contended eli lilly deliberately marketed drug treat agitation aggression hostility dementia alzheimer dementia depression generalized sleep disorder none uses approved fda largest pharmaceutical settlement us history time pfizer reached billion settlement department justice resolve criminal charges civil claims false claims pharmaceutical giant accused offlabel promotion antiinflammatory drug bextra geodon antipsychotic drug zyvox antibiotic lyrica antiepileptic drugs allegedly promoted uses approved fda therefore companys marketing caused nonreimbursable prescriptions paid medicare medicaid medicare medicaid reimburse offlabel drug six whistleblowers shared million reward false claims government investigation precipitated whistleblower suit filed debra parks false claims act alpharma agreed million settlement resolve civil criminal liability connection companys alleged offlabel marketing according government company promoted kadian morphinebased drug uses unapproved fda addition company made misrepresentations safety efficacy qui tam suit filed false claims act led astrazeneca make massive million settlement resolve civil criminal liability respect illegal promotion antipsychotic drug seroquel approved fda treat manifestations psychotic disorders fda subsequently approved seroquel shortterm treatment schizophrenia bipolar disorder bipolar january december astrazeneca promoted seroquel psychiatrists physicians certain uses approved fda including aggression alzheimer disease anger management anxiety attention deficit hyperactivity disorder bipolar maintenance dementia depression mood disorder posttraumatic stress disorder federal health programs reimburse prescriptions prescribed indications approved fda two subsidiaries johnson johnson orthomcneil pharmaceutical orthomcneiljanssen agreed pay million settle civil criminal liability result companies illegal marketing topamax antiepileptic part settlement orthomcneil agreed plead guilty one count misdemeanor violation food drug cosmetic criminal fine amounted million government recovered million damages false claims act whistleblowers filed suit false claims act stood recover collectively novartis vaccines diagnostics novartis pharmaceuticals corporation agreed pay million settle claims brought false claims act alleging offlabel promotion cystic fibrosis drug tobi allergan manufacturer botox agreed million settlement resolve civil criminal liability surrounding promotion botox treatment chronic migraines fda review approval drug novartis made settlement million including million criminal fine forfeiture offlabel promotion antiepilepsy drug trileptal approved fda treat partial seizures allegedly promoted treat pain psychiatric conditions government also accused novartis paying illegal kickbacks healthcare forest laboratories made settlement million resolve criminal civil liability related three different drugs forest laboratories pleaded guilty obstruction justice illegal distribution levothroid time unapproved new settlement also resolved allegations offlabel marketing celexa antidepressant approved treat adult depression according government forest marketed celexa use children irish pharmaceutical company Ã©lan us subsidiary agreed pay million resolve allegations company engaged offlabel promotion antiepilepsy drug zonegran eisai japanese drug marketer purchased drug Ã©lan agreed pay million settlement resolved claims illegal promotion food drug cosmetic act well civil claims filed false claims kos pharmaceuticals subsidiary abbott laboratories agreed settlement million dispose civil criminal liability resulting companys offlabel promotion illegal payment kickbacks marketing advicor niaspan department justice entered deferred prosecution agreement kos based actions taken company conduct internal investigations ongoing cooperation us subsidiary ucb belgian pharmaceutical company agreed pay million part settlement agreement resolve criminal civil liability arising alleged offlabel promotion epilepsy drug keppra ucb alleged promoted drug treatment migraine headaches use keppra received fda novo nordisk danish drug manufacturer agreed million settlement resolve allegations illegal promotion drug novoseven approved fda treat certain bleeding disorders hemophiliacs government complaint alleged numerous offlabel uses company promoted drug including coagulatory agent trauma patients general surgery cardiac surgery liver surgery liver transplants intracerebral case pfizer settlement offlabel promotion neurontin pfizer agreed settlement result whistleblower complaint filed false claims act without intervention department justice million settlement arose complaint alleged pfizer engaging illegal promotion detrol drug approved fda treat urinary incontinence offlabel abbott laboratories agreed pay million resolve criminal civil liability arising company unlawful promotion prescription drug depakote uses approved safe effective fda company misbranded depakote promoting drug control agitation aggression elderly dementia patients treat schizophrenia neither uses fda approved settlement figure represents resolution claims addition offlabel glaxosmithkline gsk agreed pay billion relating false claims arising offlabel promotion gsk promoted drugs paxil wellbutrin unapproved noncovered uses gsk also promoted asthma drug advair firstline therapy mild asthma patients even though approved medically appropriate circumstances gsk also promoted advair chronic obstructive pulmonary disease misleading claims relevant treatment guidelines gsk also promoted lamictal antiepileptic medication offlabel noncovered psychiatric uses neuropathic pain pain management gsk promoted certain forms zofran approved postoperative nausea treatment morning sickness pregnant women settlement figure represents resolution claims addition offlabel amgen agreed pay million offlabel promotion three drugs manufactured enbrel neulasta amgen promoted sale use aranesp dosing regiments indications approved fda b medically accepted indications including anemia caused cancer anemia caused chronic disease chronic anemia anemia caused myelodysplastic syndrome similarly amgen promoted drugs enbrel neulasta offlabel indications eligible coverage federal health care programs settlement figure represents resolution claims addition offlabel par pharmaceutical agreed pay million federal government various states resolve claims arising offlabel marketing par made unsubstantiated misleading representations superiority megace es generic megestrol acetate elderly patients encourage providers switch patients generic megestrol acetate megace es despite conducted wellcontrolled studies support claim greater efficacy megace es except admitted plea agreement claims settled civil settlement agreement allegations determination liability wyeth acquired pfizer agreed pay million resolve claims involving offlabel promotion immunosuppressant drug rapamune government alleged wyeth violated false claims act promoting rapamune unapproved uses medically accepted indications therefore covered medicare medicaid federal health care programs unapproved uses included nonrenal transplants conversion use switching patient another immunosuppressant rapamune using rapamune combination immunosuppressive agents listed johnson johnson agreed pay billion resolve false claims resulting offlabel promotion risperdal invega natrecor risperdal approved treat schizophrenia yet janssen johnson johnson jj subsidiary promoted risperdal physicians prescribers treated elderly dementia patients urging prescribers use risperdal treat symptoms anxiety agitation depression hostility confusion similarly although invega approved treatment schizophrenia schizoaffective disorder jj janssen marketed drug offlabel indications finally scios inc subsidiary jj launched aggressive campaign market natrecor scheduled serial outpatient infusions patients less severe heart failure use included fdaapproved label covered federal health care programs settlement figure represents resolution claims addition offlabel carefusion agreed pay million resolve allegations offlabel promotion chloraprep chloraprep approved fda preparation patient skin prior surgery injection settlement also resolves allegations period september august carefusion knowingly promoted sale chloraprep uses approved fda medically accepted indications made unsubstantiated representations appropriate uses chloraprep settlement figure represents resolution claims addition offlabel endo pharmaceuticals agreed pay million resolve civil liability false claims act offlabel promotion lidoderm government charged endo misbranded lidoderm introduced interstate commerce violation food drug cosmetic act fdca lidoderms labeling lacked adequate directions use treatment nonphn related pain including low back pain diabetic neuropathy carpal tunnel syndrome uses intended endo pharmaceuticals inc never approved august insys therapeutics reached million settlement oregon department justice resolving allegations promoted opioid drug subsys treat offlabel noncancer uses approved insys also paid new hampshire million settle allegations aggressive marketing july californiabased medical device manufacturer johnson johnson subsidiary acclarent inc agreed pay million resolve allegations marketed distributed sinus spacer product use drug delivery device without fda government alleged continued offlabel marketing even fda rejected companys request expand approved uses even though company added warning label regarding use active drug substances device july companys former ceo former vice president sales also convicted following trial ten misdemeanor counts introducing adulterated misbranded medical devices interstate november medical device company biocompatibles inc subsidiary btg plc agreed pay million resolve allegations violated false claims act causing false claims submitted government health care company allegedly promoted lc bead embolization inserted blood vessels block flow blood offlabel use drugdelivery device fdaapproved use supported substantial clinical evidence company also agreed pay additional million criminal fines forfeitures total december pharmaceutical company bristolmyers squibb agreed pay million settle claims fortythree state attorneys general concerning alleged offlabel promotion schizophrenia drug lawsuit alleged company promoted drug use pediatric populations treat dementia alzheimers elderly patients despite fact fdaapproved uses january shire plc subsidiaries entered global resolution civil fca federal state governments million settlement largely focused payment alleged kickbacks induce clinics physicians use overuse product dermagraft bioengineered human skin substitute approved fda treatment diabetic foot settlement also resolved allegations shire predecessor abh unlawfully marketed dermagraft offlabel uses approved fda made false statements inflate price dermagraft caused improper coding verification certification dermagraft claims related allegations resolved settlement brought six lawsuits filed qui tam whistleblower provisions false claims act july celgene agreed pay million government agencies settle allegations caused submission false claims fraudulent claims nonreimbursable uses drugs revlimid thalomid medicare state medicaid addition listing offlabel promotion covered conduct settlement agreement separately covered alleged false misleading statements celgene made drugs including concealing minimizing adverse july form celgene disclosed resolved matter full million including fees case brought false claims act beverly brown former celgene sales september aegerion pharmaceuticals agreed pay million resolve allegations violated federal marketing rules promoting cholesterol medication juxtapid resulting violation federal false claims act state settlement resolved allegations aegerion promoted juxtapid offlabel uses approved fda made false misleading statements medical practitioners regarding drug violated riskmanagement regulations designed ensure safe use broke antikickback laws charity addition civil false claims act liability aegerion also agreed guilty plea involving conduct pay criminal fine forfeiture december boehringer ingelheim pharmaceuticals inc agreed pay million settle claims state attorneys general states plus attorney general district columbia engaged offlabel promotion drugs aggrenox atrovent combivent httpsenwikipediaorgwikilistofofflabelpromotionpharmaceuticalsettlements